trans-4-(2-methylaminoethyl)cyclohexanecarboxylic acid hydrochloride | 824430-05-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-4-(2-methylaminoethyl)cyclohexanecarboxylic acid hydrochloride
• CAS: 824430-05-9
• 化学式: C₁₀H₁₉NO₂*ClH
• 分子量: 221.727
• InChiKey: IMPKAKNLJQGOCU-JUAUBFSOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  14.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.33
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  trans-4-(2-methylaminoethyl)cyclohexanecarboxylic acid hydrochloride 在 草酰氯 、 N,N-二甲基甲酰胺 、 六甲基二硅氮烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Cytotoxic Effects of Combination of Oxidosqualene Cyclase Inhibitors with Atorvastatin in Human Cancer Cells

  摘要：

  Ten oxidosqualene c-yclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical structure classes were evaluated as potential anticancer agents against human cancer cells from various tissue origins and nontumoral human-brain-derived endothelial cells. Inhibition of cancer cell growth was demonstrated at micromolar concentrations, comparable to the concentrations of statins necessary for antitumor effect. Human glioblastoma cells were among the most sensitive cells. These compounds were also able to decrease the proliferation of angiogenic brain-derived endothelial cells, as a model of tumor-induced neovasculation. Additive effects in human glioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endothelial cells. Thus, not only statins targeting the 3-hydroxy-3-methylglutaryl coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting new therapeutic opportunities of combined anti-cholesterol agents for dual treatment of glioblastoma.

  DOI：

  10.1021/jm300256z
• 作为产物：
  描述：

  trans-acetic acid 4-(2-(tert-butoxycarbonylamino)ethyl)cyclohexylmethyl ester 在 盐酸 、 sodium periodate 、 ruthenium(III) chloride monohydrate 、 sodium hydride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.5h， 生成 trans-4-(2-methylaminoethyl)cyclohexanecarboxylic acid hydrochloride
  参考文献：
  名称：

  Cytotoxic Effects of Combination of Oxidosqualene Cyclase Inhibitors with Atorvastatin in Human Cancer Cells

  摘要：

  Ten oxidosqualene c-yclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical structure classes were evaluated as potential anticancer agents against human cancer cells from various tissue origins and nontumoral human-brain-derived endothelial cells. Inhibition of cancer cell growth was demonstrated at micromolar concentrations, comparable to the concentrations of statins necessary for antitumor effect. Human glioblastoma cells were among the most sensitive cells. These compounds were also able to decrease the proliferation of angiogenic brain-derived endothelial cells, as a model of tumor-induced neovasculation. Additive effects in human glioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endothelial cells. Thus, not only statins targeting the 3-hydroxy-3-methylglutaryl coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting new therapeutic opportunities of combined anti-cholesterol agents for dual treatment of glioblastoma.

  DOI：

  10.1021/jm300256z

文献信息

• Aminoalkylamide substituted cyclohexyl derivatives
  申请人：Ackermann Jean

  公开号：US20050065210A1

  公开（公告）日：2005-03-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , U, V, W, k and m are as defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasit infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、R5、U、V、W、k和m在说明书和权利要求中定义，并且它们的药学上可接受的盐和/或药学上可接受的酯。该化合物可用于治疗和/或预防与2,3-氧化甾醇-鲨烯环化酶有关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌感染、寄生虫感染、胆结石、肿瘤和/或增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• Hydroxyalkylamide derivatives
  申请人：Ackermann Jean

  公开号：US06965048B2

  公开（公告）日：2005-11-15

  The present invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X, W, m and n are as defined hereinabove. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及式（I）的化合物，其中R1，R2，R3，R4，X，W，m和n的定义如上所述。这些化合物可用于治疗和/或预防与2,3-氧化齐墩果醇-甾醇环化酶相关的疾病，例如高胆固醇血症，高脂血症，动脉硬化，血管疾病，真菌感染，寄生虫感染，胆结石，肿瘤和/或增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• US6965048B2
  申请人：——

  公开号：US6965048B2

  公开（公告）日：2005-11-15
• US7442791B2
  申请人：——

  公开号：US7442791B2

  公开（公告）日：2008-10-28